EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

Christopher G Bunick iD, Alan D Irvine iD, Jonathan I Silverberg iD, Emma Guttman-Yassky iD, Mona Shahriari, Xinghua Gao iD, Stephan Weidinger iD, Norito Katoh, Namita Vigna, Deanne M Dilley, Elvira D'Andrea, Henrique D Teixeira und 2 weitere

Journal of the European Academy of Dermatology and Venereology · 2026-05 · 40 (5) · 856-866

DOI: 10.1111/jdv.70172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 15.11.2025. Verfasst von Christopher G Bunick und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Program in Translational Biomedicine, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD) is a common inflammatory skin disease characterized by eczematous lesions, dry skin and intense pruritus. Upadacitinib, a selective JAK1 inhibitor approved for moderate‐to‐severe AD in adults and adolescents, is a once‐daily oral treatment.

Objectives

To evaluate the long‐term safety profile of the treatment of moderate‐to‐severe AD with upadacitinib 15 mg (UPA15) or 30 mg (UPA30) across 6 years.

Methods

Safety data for adverse events (AEs), including treatment‐emergent adverse events (TEAEs) and adverse events of special interest (AESIs) from three global phase 3 studies (MeasureUp 1, MeasureUp 2 and ADUp), were analysed. Data were included for all adolescent and adult patients (12–75 years) receiving at least 1 dose of UPA15 or UPA30 across 6 years.

Results

Serious adverse event rates were similar for UPA15 (6.6 events [E] per 100 patient‐years [PY]) and UPA30 (7.4 E/100 PY). Nasopharyngitis was the most frequently reported adverse event (UPA15, 9.8 E/100 PY; UPA30, 9.3 E/100 PY) excluding COVID‐19. Event rates for serious infections were similar for both groups (UPA15, 2.2 E/100PY; UPA30, 2.6 E/100 PY). Rates of most AESIs were similar between UPA15 and UPA30, except for those known to be dose dependent: herpes zoster, hepatic disorder, neutropenia and CPK elevation. Adjudicated major adverse cardiovascular event incidence rates were 0.2 n/100PY and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHeterocyclic Compounds, 3-RingAdolescentAdultAgedChildFemaleHumansMaleMiddle AgedYoung AdultJanus Kinase InhibitorsRandomized Controlled Trials as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

atopic dermatitisclinical trialeczemasafetyupadacitinib

Substanzen

Heterocyclic Compounds, 3-RingJanus Kinase Inhibitorsupadacitinib

Autor:innen und Institutionen

  • Department of Dermatology and Program in Translational Biomedicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
  • Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
  • Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Central CT Dermatology Research PLLC, Cromwell, Connecticut, USA.

ORCID-Profile: Christopher G Bunick, Alan D Irvine, Jonathan I Silverberg, Emma Guttman-Yassky, Xinghua Gao, Stephan Weidinger

Förderung

  • AbbVie

Zitieren

APA

Bunick, C. G., Irvine, A. D., Silverberg, J. I., Guttman-Yassky, E., Shahriari, M., Gao, X., Weidinger, S., Katoh, N., Vigna, N., Dilley, D. M., D'Andrea, E., Teixeira, H. D., Platt, A. M., & Levy, G. F. (2026). Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years. Journal of the European Academy of Dermatology and Venereology, 40(5), 856-866. https://doi.org/10.1111/jdv.70172

Vancouver

Bunick CG, Irvine AD, Silverberg JI, Guttman-Yassky E, Shahriari M, Gao X, et al. Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years. Journal of the European Academy of Dermatology and Venereology. 2026;40(5):856-866. doi:10.1111/jdv.70172

BibTeX
@article{Bunick2026,
  author = {Bunick, Christopher G and Irvine, Alan D and Silverberg, Jonathan I and Guttman-Yassky, Emma and Shahriari, Mona and Gao, Xinghua and Weidinger, Stephan and Katoh, Norito and Vigna, Namita and Dilley, Deanne M and D'Andrea, Elvira and Teixeira, Henrique D and Platt, Andrew M and Levy, Gweneth F},
  title = {Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {5},
  pages = {856--866},
  doi = {10.1111/jdv.70172}
}
Kostenlos starten →